Hernexeos Dosage
Generic name: ZONGERTINIB 60mg
Dosage form: tablets
Medically reviewed by Drugs.com. Last updated on Aug 8, 2025.
Patient Selection
Select patients for treatment of unresectable or metastatic NSCLC based on the presence of HER2 (ERBB2) tyrosine kinase domain activating mutations in tumor specimens. Information on FDA-approved tests for HER2 (ERBB2) tyrosine kinase domain activating mutations is available at: http://www.fda.gov/CompanionDiagnostics.
Recommended Dosage and Administration
The recommended dosage of HERNEXEOS is based on body weight:
- < 90 kg: 120 mg
- ≥ 90 kg: 180 mg
Take HERNEXEOS orally once daily with or without food until disease progression or unacceptable toxicity. Swallow HERNEXEOS tablets whole with water. Do not split, crush, or chew tablets.
Dosage Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are presented in Table 1.
| Current HERNEXEOS Dose | First Reduction | Second Reduction |
|---|---|---|
| 180 mg | 120 mg | 60 mg |
| 120 mg | 60 mg | Permanently discontinue |
| Permanently discontinue HERNEXEOS in patients who are unable to tolerate 60 mg once daily. | ||
The recommended dosage modifications for adverse reactions are presented in Table 2.
| Adverse Reaction | Severity | Dosage Modification |
|---|---|---|
| ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Events; ULN = upper limit of normal | ||
| Hepatotoxicity | Grade 3 or 4 ALT and/or AST without increased total bilirubin |
|
| Grade 3 total bilirubin |
|
|
| Grade 4 total bilirubin |
|
|
| ALT or AST ≥ 3× ULN with total bilirubin ≥ 2× ULN |
|
|
| Left Ventricular Dysfunction |
LVEF 40 to 50% and decrease from baseline of 10 to 19% |
|
| LVEF 20 to 39% or ≥ 20% decrease from baseline |
|
|
| Symptomatic Congestive Heart Failure |
|
|
| Interstitial Lung Disease/Pneumonitis |
Grade 2 |
|
| Grade 3 or Grade 4 |
|
|
| Diarrhea | Grade 2 |
|
| Grade 2 lasting ≥ 2 days despite anti-diarrheal treatment |
|
|
| Grade 3 or Grade 4 |
|
|
| Other Adverse Reactions |
Grade 3 |
|
| Grade 4 |
|
|
Dosage Modifications for Drug Interactions
Strong CYP3A Inducers
Avoid concomitant use of strong CYP3A inducers with HERNEXEOS.
If concomitant use cannot be avoided, increase the HERNEXEOS dose based on body weight:
- < 90 kg: from 120 mg to 240 mg
- ≥ 90 kg: from 180 mg to 360 mg
After discontinuing a CYP3A inducer, resume the HERNEXEOS dose (7 to 14 days after discontinuing the CYP3A inducer) that was taken prior to initiating the CYP3A inducer.
More about Hernexeos (zongertinib)
Patient resources
Professional resources
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
